EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice

Alexandra Cambier iD, Jennifer Da Silva, Julie Bex, Fanny Canesi, Lison Lachize Neanne, Aurélie Sannier, Hélène Mathieu iD, Erwan Boedec, Amandine Badie, Renato C Monteiro

PLOS One · 2025

DOI: 10.1371/journal.pone.0318581 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Alexandra Cambier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Service de Néphrologie pédiatrique-hémodialyse, CHU Sainte Justine, Montréal, Canada. Hauptthemen laut MEDLINE: Glomerulonephritis, IGA, Receptors, Transferrin, TOR Serine-Threonine Kinases, Antigens, CD. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ORKID, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and hypothesis IgA nephropathy (IgAN) is the most common glomerulonephritis and major cause of renal failure worldwide. Its pathogenesis involves galactose deficient IgA1-immune complexes containing soluble IgA Fc receptor (sCD89). Both IgA1 and sCD89 bind independently to the transferrin receptor (TfR1, CD71), a mesangial IgA1 receptor. Here, we hypothesize that sCD89 plays a pathogenic role in IgAN by driving a tri-partite IgA1-sCD89-CD71 complex inducing activation in situ of the mTOR (mammalian target of rapamycin) signaling pathway in mesangial cells and contributing to disease progression. mTOR inhibition may disrupt this pathogenic axis, reducing IgA1 and sCD89 deposits, modulating CD71 expression, and alleviating disease manifestations. Here, we investigated the role of sCD89 and a mTOR inhibitor using humanized mouse models of IgAN expressing CD89 and/or IgA1.

Methods

Single cell and RNAseq data were obtained from public IgAN dataset and immunostaining was performed on childhood IgAN (cIgAN) biopsies. Human mesangial cells (HMCs) stimulation by recombinant sCD89 (rsCD89) was followed by western blot analysis. Pre-clinical assays with mTOR inhibitor (Everolimus) by oral gavage were performed using young α1 KI mice injected with rsCD89 for 25 days (preventive protocol) and adult α1 KI CD89 Tg mice (treated protocol) for 75 days. Proteinuria, renal function, and circulating immune complexes (CICs) were analyzed and kidneys were harvested for histology.

Results

RNAseq revealed increased TfR1 and mTOR expression in mesangial cells from IgAN patients. TfR1 upregulation was confirmed in cIgAN biopsies. sCD89 stimulation induced HMC TfR1 expression and phosphorylation of mTOR, Akt and S6K1. Everolimus treatment prevented or reverted mesangial IgA1 and C3 deposits and also decreased mesangial TfR1 and cell proliferation. Everolimus impaired levels of sCD89- and IgA-CIC, proteinuria, as well as renal function.

Conclusion

These findings highlight the critical role of the sCD89-TfR1-mTOR axis in IgAN pathogenesis and support the use of mTOR inhibitors as a novel therapeutic approach. This approach could significantly improve outcomes by slowing disease progression and minimizing the systemic toxic effects of current immunosuppressive therapies. This is particularly crucial for pediatric patients, where the only approved treatment – steroids – has severe side effects, including detrimental impacts on bone health and growth.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, IGAReceptors, TransferrinTOR Serine-Threonine KinasesAntigens, CDReceptors, FcMTOR InhibitorsAnimalsHumansMiceImmunoglobulin ADisease Models, AnimalMesangial CellsEverolimusSignal Transduction

Substanzen

Receptors, TransferrinTOR Serine-Threonine KinasesCD71 antigenAntigens, CDReceptors, FcImmunoglobulin AMTOR InhibitorsEverolimus

Autor:innen und Institutionen

  • Service de Néphrologie pédiatrique-hémodialyse, CHU Sainte Justine, Montréal, Canada.
  • Axe Maladies immunitaires et cancer, Centre de Recherche Azrieli, Université de Montréal, CHU Sainte Justine, Montréal, Canada.
  • Centre d'expertise sur les maladies rares médiées par le complément, CHU Sainte Justine, Montréal, Canada.
  • Université de Paris Cité, Centre de Recherche sur l'Inflammation (CRI), INSERM U1149 & CNRS E8252, Inflamex Laboratory of Excellence, Paris, France.
  • Université de Paris Cité, Service anatomopathologie, Bichat Hospital, Assistance Publique Hôpitaux de Paris, Paris, France.
  • Université de Paris Cité, Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM UMR1266, Biochemistry and Biophysics facility, Paris, France.

ORCID-Profile: Alexandra Cambier, Hélène Mathieu

Förderung

  • ORKID
  • Agence Nationale de la Recherche
  • Fondation pour la Recherche Médicale
  • IMEA
  • LabEx Inflamex

Zitieren

APA

Cambier, A., Da Silva, J., Bex, J., Canesi, F., Neanne, L. L., Sannier, A., Mathieu, H., Boedec, E., Badie, A., & Monteiro, R. C. (2025). Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice. PLOS One. https://doi.org/10.1371/journal.pone.0318581

Vancouver

Cambier A, Da Silva J, Bex J, Canesi F, Neanne LL, Sannier A, et al. Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice. PLOS One. 2025. doi:10.1371/journal.pone.0318581

BibTeX
@article{Cambier2025,
  author = {Cambier, Alexandra and Da Silva, Jennifer and Bex, Julie and Canesi, Fanny and Neanne, Lison Lachize and Sannier, Aurélie and Mathieu, Hélène and Boedec, Erwan and Badie, Amandine and Monteiro, Renato C},
  title = {Blockade of mTOR ameliorates IgA nephropathy by correcting CD89 and CD71 dysfunctions in humanized mice},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0318581}
}
Kostenlos starten →